Organoids Technology: A Pathway to the Permanent Treatment of Pulmonary Diseases

Atefeh Fakharian; Reyhaneh  Zahiri; Seyed Bashir Mirtajani

doi:10.18502/jimc.v5i2.10477

Atefeh Fakharian Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Reyhaneh Zahiri Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Seyed Bashir Mirtajani Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/jimc.v5i2.10477

Keywords: Lung organoids, Pulmonary diseases, SARS-CoV-2

Abstract

Organoids are a miniature, simplified version of a human organ that are produced in three dimensions in the laboratory and show the true anatomical array. These organelles originate from one or more cells - embryonic stem cells or induced multipotent stem cells - that can organize themselves in three-dimensional culture media. The use of stem cells due to the unlimited capacity of tissue division and regeneration is a great promise as a therapeutic tool. These three-dimensional models of human tissue can be used to test drugs before they are tested on humans. Lung organoids are one of the different types of organoids that, like other organoids, can be formed through a process of self-organizing stem cells or specific parts of an organ. These organoids can also be utilized as a useful tool for screening drugs and vaccines for infections such as the novel SARS-COV-2 infection. The aim of this study was to investigate the potential of lung organoids in the treatment of pulmonary diseases.